Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
Decision snapshot: ORCL stock price vs HUM: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at HUM's multiple
Needs HUM P/E.
Implied fair value · at ORCL's multiple
Needs ORCL P/E.
Price unavailable
Metric by metric
Where each company leads, and how wide the gap is.
Growth edge
Reported gross margin
Operating income + D&A
Lower is better
Not comparable
Lower leverage
Statements
Annual statements in reported currencies, with calculations and source evidence.
Values retain reported currencies and share bases. Select a figure to inspect its period, calculation and filing inputs. Differences require compatible units and periods.
Explore enterprise value and market valuation multiples in the valuation sections.
Trendline
12 period-end years of reported revenue, earnings, and margins. Periods and currencies are shown with the data.
Price framework
USD market cap plus reported borrowing debt, less cash and equivalents. This EV proxy excludes investments, preferred stock and noncontrolling-interest adjustments.
Complete market value, debt and cash evidence is required for enterprise value.
Complete market value, debt and cash evidence is required for enterprise value.
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
ORACLE CORP · implied price per share
Latest annual free cash flow must be positive to qualify the filing-backed baseline.
HUMANA INC · implied price per share
Bear
$238.74
Base
$269.81
Bull
$310.28
Balance sheet health
Inspect reported liquidity and leverage alongside historical financial-health checks.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Not enough data to score either balance sheet.
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
Microsoft Corporation
ORCL vs MSFT
Amazon.com, Inc.
ORCL vs AMZN
Alphabet Inc.
ORCL vs GOOGL
International Business Machines Corporation
ORCL vs IBM
Cisco Systems, Inc.
ORCL vs CSCO
Salesforce, Inc.
ORCL vs CRM
UNITEDHEALTH GROUP INC
ORCL vs UNH
Elevance Health, Inc.
ORCL vs ELV
CVS HEALTH Corp
ORCL vs CVS
Cigna Group
ORCL vs CI
CENTENE CORP
ORCL vs CNC
Oscar Health, Inc.
ORCL vs OSCR
Cash excludes investments. EBITDA is an operating-income-plus-D&A proxy. Missing borrowing categories remain unavailable; select a value to inspect its inputs.
LLM-powered synthesis
An explanation of the financial evidence. Check its snapshot date against the figures above.
This explanation uses an earlier data snapshot or evidence version. Review its generation date and the current figures, or refresh after signing in.
If you believe ORCL can sustain its 17.3% revenue growth and 30.6% operating margin, then the stock looks attractive to own or add because the P/E discount to HUM and the 55.2% implied upside outweigh the weaker 4/9 Piotroski reading.
ORCL trades at a 25.2x P/E versus HUM at 39.1x, yet the model implies 55.2% upside to $228.10 from a current price of $147.02. The valuation gap is reinforced by ORCL's stronger profitability profile, while HUM-implied range suggests meaningful upside but also wide dispersion.
Supporting Metrics
